Prognostic value of brain abnormalities for cognitive functioning in cerebral palsy: A prospective cohort study.


Journal

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
ISSN: 1532-2130
Titre abrégé: Eur J Paediatr Neurol
Pays: England
ID NLM: 9715169

Informations de publication

Date de publication:
May 2021
Historique:
received: 03 11 2020
revised: 01 03 2021
accepted: 07 03 2021
pubmed: 6 4 2021
medline: 29 6 2021
entrez: 5 4 2021
Statut: ppublish

Résumé

Brain abnormalities in cerebral palsy (CP) are known to relate to motor outcome; however, their association with cognitive functioning is less clear. 1) To investigate the prognostic value of brain abnormalities for cognitive functioning; 2) To explore the added value of prognostic variables across ICF domains: motor function, epilepsy, gestational age, birthweight and educational level of the parents. We retrospectively analyzed brain MRI scans of 75 children with CP (GMFCS level I-V, 36% born preterm), as part of a longitudinal study. MRI classification: qualitative classification of brain abnormality pattern and semi-quantitative grading of the extent of damage. Cognitive functioning, measured as non-verbal intelligent quotient (IQ), was dichotomized into 'impaired cognition' (IQ ≤ 70) and 'normal' (IQ > 70). Multivariable logistic regression produced odds ratios (OR) with 95% confidence interval (C.I.) of risk factors for impaired cognition. Overall, 27% of the tested participants had a non-verbal IQ below 70 and 36% of the participants was classified as 'having impaired cognition'. At a young age, a higher degree of white matter damage (OR 1.6, 95% C.I. 0.97-2.67) and a more severe GMFCS level (OR 3.2, 95% C.I. 1.70-5.98) are risk factors for impaired cognition at school-age (4-7 years of age). This model correctly predicts 89% of the cases. Brain damage alone predicts the presence of impaired cognition in 71% of the cases. Brain MRI characteristics and GMFCS level at a young age can each help identify children with CP at risk for impaired cognition at school age and together have a strong predictive value.

Identifiants

pubmed: 33819831
pii: S1090-3798(21)00064-7
doi: 10.1016/j.ejpn.2021.03.010
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

56-65

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None of the authors has any competing interest to declare.

Auteurs

Irene Moll (I)

Department of Neurology, Maastricht University Medical Center, the Netherlands; Department of Nutrition and Movement Sciences and School of Mental Health and Neuroscience, Maastricht University, the Netherlands. Electronic address: irene.moll@maastrichtuniversity.nl.

Jeanine M Voorman (JM)

Department of Rehabilitation, Physical Therapy Science and Sports and Center of Excellence for Rehabilitation Medicine, UMC Utrecht Brain Center, University Medical Center Utrecht and De Hoogstraat Rehabilitation, Utrecht, the Netherlands.

Marjolijn Ketelaar (M)

Center of Excellence for Rehabilitation Medicine; UMC Utrecht Brain Center, University Medical Center Utrecht, and De Hoogstraat Rehabilitation, Utrecht, the Netherlands.

Petra E van Schie (PE)

Department of Rehabilitation Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands.

Jan Willem Gorter (JW)

CanChild, Department of Pediatrics, School of Rehabilitation Science, McMaster University, Hamilton, Canada.

Maarten H Lequin (MH)

Department of Radiology, UMC Utrecht, the Netherlands.

Linda S de Vries (LS)

Department of Neonatology, UMC Utrecht, the Netherlands.

R Jeroen Vermeulen (RJ)

Department of Neurology, Child Neurology, Maastricht University Medical Center and School of Mental Health and Neuroscience, Maastricht University, the Netherlands. Electronic address: Jeroen.vermeulen@mumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH